Trial Profile

Phase I Trial of TGFB2-Antisense-GMCSF Gene Modified Autologous Tumor Cell (TAG) Vaccine for Advanced Cancer.

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 09 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bi-shRNAfurin-GM-CSF-loaded tumour cell vaccine (Primary)
Indications Solid tumours
Focus Adverse reactions; First in man
Acronyms Auto TAG

Most Recent Events

19 Dec 2016 According to a Gradalis media release, status changed from active, no longer recruiting to completed.
20 Mar 2013 Planned End Date changed from 1 May 2012 to 1 Dec 2016 as reported by ClinicalTrials.gov.
20 Mar 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com